



# Tatva Chintan Pharma Chem Limited

(CIN:L24232GJ1996PLC029894)



Date: 11 July 2023

Ref. No.: TCPCL/SEC/2023-24/00027

To,  
**The General Manager,**  
**Corporate relationship department,**  
**BSE Limited**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai-400 001  
**Scrip Code: 543321**

**The Manager,**  
**Listing department,**  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block-G,  
Bandra-Kurla, Complex Bandra(E),  
Mumbai-400 051  
**Scrip Symbol: TATVA**

**Subject: Outcome of the Board Meeting held on 11 July 2023**

Dear Sir / Madam,

In continuation to our intimation dated 06 July 2023 and pursuant to Regulation 30 and 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the “**SEBI Listing Regulations**”), we wish to inform you that the Board of Directors of Tatva Chintan Pharma Chem Limited (the “**Company**”) in its meeting held today i.e. 11 July 2023 have *inter alia* approved the following:

- raising further capital and to create, offer, issue and allot such number of equity shares having face value of Rs. 10 each of the Company (“**Equity Shares**”) and/or equity linked instruments, including convertible preference shares, non-convertible debt instruments along with warrants, fully convertible debentures, partly convertible debentures, and/or any other securities convertible into equity shares (including warrants or otherwise), global depository receipts, American depository receipts, foreign currency convertible bonds (collectively, “**Securities**”) or any combination of Securities, through public and/or private offerings and/or by way of qualified institutions placement, or any combination thereof, in one or more tranches, for an aggregate amount not exceeding Rs. 2,000 million, in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018, as amended, (“**SEBI ICDR Regulations**”) and all other applicable laws, as may be considered appropriate, subject to shareholders approval and government / regulatory / statutory and any other approvals and requirements, as applicable.
- approval of notice to seek requisite members approval by way of special resolution through Postal Ballot.
- the constitution of an ‘Fund Raising Committee’ for including, but not limited to, taking necessary decision, resolve the difficulties/obstacles which may arise with respect to company’s proposed fund raising, and to enter into any arrangement for managing and marketing the proposed fund raise and to appoint, in its absolute discretion, book running lead managers, legal advisor(s), escrow bank(s)/agent(s) and other agents as may be required in order to facilitate or consummate the proposed fund raise.

The details, as required to be disclosed under Regulation 30 read with SEBI Circular no CIR/CFD/CMD/4/2015 dated 09 September 2015, are also enclosed as **Annexure A**.

The above information shall be made available on the website of the Company at [www.tatvachintan.com](http://www.tatvachintan.com).

The meeting of the Board of Directors commenced at 05:00 P.M. and concluded at 06:35 P.M.

This is for your information and records.

Thanking You.

Yours faithfully,  
**For Tatva Chintan Pharma Chem Limited**

**Ishwar Nayi**  
**Company Secretary and Compliance Officer**  
**M. No.: A37444**

**Encl.: As Above**



# Tatva Chintan Pharma Chem Limited

(CIN:L24232GJ1996PLC029894)



## Annexure A

The details as required to be disclosed under Regulation 30 read with SEBI Circular dated 09 September 2015:

Sr. No.	Particulars	Details
1	Type of securities proposed to be issued (viz., equity shares, convertibles, etc.);	Equity Shares and/or equity linked instruments, including convertible preference shares, non-convertible debt instruments along with warrants, fully convertible debentures, partly convertible debentures, and/or any other securities convertible into equity shares (including warrants or otherwise), global depository receipts, American depository receipts, foreign currency convertible bonds
2	Type of issuance (further public offering, rights issue, depository receipts (ADR / GDR), qualified institutions placement, preferential allotment etc.);	Public and/or private offerings and/or by way of qualified institutions placement ("QIP"), or any combination thereof.
3	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);	Up to an aggregate amount not exceeding Rs. 2,000 million or an equivalent amount thereof at such price or prices (inclusive of such premium as may be fixed on such Securities) as may be permissible under applicable law
4	In case of preferential issue the listed entity shall disclose the following additional details to the stock exchange(s): To be determined by the Board or a duly constituted committee thereof	
5	In case of bonus issue the listed entity shall disclose the following additional details to the stock exchange(s): Not Applicable	
6	In case of issuance of depository receipts (ADR/GDR) or FCCB the listed entity shall disclose following additional details to the stock exchange(s): To be determined by the Board or a duly constituted committee thereof	
7	In case of issuance of debt securities or other non-convertible securities the listed entity shall disclose following additional details to the stock exchange(s): Not Applicable	
8	Any cancellation or termination of proposal for issuance of securities including reasons thereof: Not Applicable	

**Registered Office and Factory :** Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.

**Dahej SEZ Unit :** Plot No. Z/103/F/1 & 2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.

**Corporate Office and R & D Center (DSIR Approved) :** Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.

**Telephone No. :** +91 75748 48533 / 34 **Fax :** +91 265 263 8533 **E-mail :** cs@tatvachintan.com **Website :** www.tatvachintan.com